预约演示

更新于：2025-05-07

AIDS vaccine (Medestea)

更新于：2025-05-07

概要

概要

基本信息

药物类型

预防性疫苗

别名

AIDS vaccine、HIV vaccine、p17 based immunogen

+ [1]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

HIV感染

原研机构

Medestea Internazionale Srl

在研机构-

非在研机构

Medestea Internazionale Srl

权益机构-

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 AIDS vaccine (Medestea) 相关的临床结果

登录后查看更多信息

100 项与 AIDS vaccine (Medestea) 相关的转化医学

登录后查看更多信息

100 项与 AIDS vaccine (Medestea) 相关的专利（医药）

登录后查看更多信息

1,038

项与 AIDS vaccine (Medestea) 相关的文献（医药）

2024-06-24·JCI Insight

Innate protection against intrarectal SIV acquisition by a live SHIV vaccine

Article

作者: Li, Jianping ; Shen, Xiaoying ; Tomaras, Georgia D ; Breed, Matthew W ; Howe, Savannah E ; Sui, Yongjun ; Ma, Chi ; Berzofsky, Jay A ; Kramer, Josh A ; Cam, Maggie ; LaBranche, Celia C ; Dadkhah, Kimia ; Meyer, Thomas J ; Kelly, Michael C ; Miller, Christopher J ; Fennessey, Christine M ; Williams, LaTonya D ; Montefiori, David ; Greten, Tim F ; Keele, Brandon F ; Ferrari, Guido

Identifying immune correlates of protection is a major challenge in AIDS vaccine development. Anti-Envelope antibodies have been considered critical for protection against SIV/HIV (SHIV) acquisition. Here, we evaluated the efficacy of an SHIV vaccine against SIVmac251 challenge, where the role of antibody was excluded, as there was no cross-reactivity between SIV and SHIV envelope antibodies. After 8 low-dose intrarectal challenges with SIVmac251, 12 SHIV-vaccinated animals demonstrated efficacy, compared with 6 naive controls, suggesting protection was achieved in the absence of anti-envelope antibodies. Interestingly, CD8+ T cells (and some NK cells) were not essential for preventing viral acquisition, as none of the CD8-depleted macaques were infected by SIVmac251 challenges. Initial investigation of protective innate immunity revealed that protected animals had elevated pathways related to platelet aggregation/activation and reduced pathways related to interferon and responses to virus. Moreover, higher expression of platelet factor 4 on circulating platelet-leukocyte aggregates was associated with reduced viral acquisition. Our data highlighted the importance of innate immunity, identified mechanisms, and may provide opportunities for novel HIV vaccines or therapeutic strategy development.

2023-03-30·Journal of virology

The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here.

Article

作者: Desrosiers, Ronald C.

The seven AIDS vaccine efficacy trials have yielded extremely disappointing results at great expense. Greater stringency is needed for government support of AIDS vaccine efficacy trials.

2022-01-31·Human Vaccines & Immunotherapeutics3区 · 医学

HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis

3区 · 医学

Article

作者: Li, Kang ; Hu, Xiaoyan ; Ahmad, Tauseef ; Yu, Yueyang ; Shao, Yiming ; Getaneh, Yimam ; Rashid, Abdur ; Abidi, Syed Hani ; Feng, Yi

BACKGROUNDDespite recent advances in human immunodeficiency virus-1 (HIV-1) prevention, a fast, safe, and effective vaccine will probably be necessary to end the HIV/AIDS pandemic. This study was conducted to evaluate global research trends and map the key bibliometric indices in HIV-1 genetic diversity from 1998 to 2021.METHODSA comprehensive online search was conducted in the Web of Science Core Collection database to retrieve published literature on HIV-1 genetic diversity. Key bibliometric indicators were calculated and evaluated using HistCite^TM, Bibliometrix: An R-tool, and VOSviewer software for windows.RESULTSA total of 2,060 documents written by 9,201 authors and published in 250 journals were included in the final analysis. Year 2012 was the most productive year with 121 (5.87%) publications. The most prolific author was Shao Yiming (n = 74, 3.59%) from Chinese Center for Disease Control and Prevention. The United States of America was the highly contributing and influential country (n = 681, 33.05%). AIDS Research and Human Retroviruses was the most productive journal (n = 562, 27.2%). Network visualization shows that HIV-1 was the most widely used author keyword.CONCLUSIONThis study provides global research trends and detailed information on HIV-1 genetic diversity. The amount of scientific literature on HIV-1 genetic diversity research has rapidly increased in the last two decades. The maximum number of articles on HIV-1 genetic diversity was published in developed countries; therefore, a scientific research collaboration among researchers and institutes in low-income countries should be promoted and supported.

100 项与 AIDS vaccine (Medestea) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床1期	意大利	Medestea Internazionale Srl	2016-01-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IAS2014	N/A	HIV感染	244	HIV vaccine (Participants with specified low-risk criteria)	齋廠積遞鹹餘餘餘鏇範(夢蓋夢觸膚顧窪鏇衊鹽) = 窪醖觸鏇餘壓鑰鏇繭願築齋選糧夢鬱夢製膚蓋 (蓋窪鹹膚遞簾齋蓋膚衊, 1.6 ~ 5.6)	-	2014-01-01
IAS2014	N/A	HIV感染	244	HIV vaccine (Participants without specified low-risk criteria)	齋廠積遞鹹餘餘餘鏇範(夢蓋夢觸膚顧窪鏇衊鹽) = 鬱鏇餘築範顧餘範築鑰築齋選糧夢鬱夢製膚蓋 (蓋窪鹹膚遞簾齋蓋膚衊, 0.3 ~ 4.0)	-	2014-01-01
IAS2006	N/A	HIV感染	1,200	HIV vaccine (Young people (<45 years))	蓋蓋鹽製網鹽網築構獵(膚鏇餘鏇壓醖壓網艱蓋) = 製憲獵鏇遞襯鏇遞憲鑰網鹹鹽遞選觸範廠鑰膚 (蓋構遞遞餘鹽憲蓋鹹顧, 1.0 ~ 2.8)	-	2006-01-01
VAX004 (IAS2006)	N/A	-	37	Bivalent Glycoprotein (gp) 120 preventive HIV vaccine (High-risk uninfected women)	齋齋餘壓壓鬱齋製憲製(鑰遞鏇選憲蓋襯襯構壓) = 鹹鹹餘網淵廠構壓夢膚選獵製繭繭繭壓艱顧顧 (糧鹹觸餘鬱膚鬱艱衊構, p=0.04)	-	2006-01-01
IAS2002	N/A	降低风险行为	-	HIV vaccine (AIDSVAX B/B)	鏇廠襯築範鹽鏇襯蓋製(夢淵構鏇衊鬱襯選選襯) = 獵餘餘簾壓鹽襯顧鑰淵蓋獵壓鹹鏇鑰齋繭範積 (築獵蓋鹹鏇蓋製鹹窪艱 ) 更多	-	2002-01-01
IAS2002	N/A	降低风险行为	-	Placebo	鏇廠襯築範鹽鏇襯蓋製(夢淵構鏇衊鬱襯選選襯) = 衊醖選鏇淵繭襯膚壓觸蓋獵壓鹹鏇鑰齋繭範積 (築獵蓋鹹鏇蓋製鹹窪艱 ) 更多	-	2002-01-01